Avelumab in combinations for lung cancer and update from ALEX study

Bookmark and Share
Published: 4 Jun 2018
Views: 1138
Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Dr Shaw speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the JAVELIN 101 trial of avelumab in combination with either criztonib or lorlatinib

She reports low efficacy and limiting toxicities in the crizotinib arm, whereas lorlatinib was better tolerated and more efficacious.

Dr Shaw also presents updates from the ALEX trial of alectinib, with longer follow up and a median PFS now available, and considers its role in future trials and combinations.